Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Gyre Therapeutics Inc.

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Reports Second Quarter 2025 and Year-to-Date Financial Results and Provides Business and Leadership Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Closing of its Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces First Dosing in Phase 1 Trial of F230 for Pulmonary Arterial Hypertension in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics’ Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces NMPA Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial Evaluating F351 for CHB-Associated Liver Fibrosis in Journal of Clinical and Translational Hepatology
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Gyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Gyre Therapeutics Inc.
Via GlobeNewswire
Tickers GYRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.